Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial
Background: Chronic Kidney Disease (CKD) is a major public health problem with a global prevalence of approximately 13% with the majority stage 3 and is a global threat to health in general and for developing countries in particular, because therapy is expensive and life-long. In India 90% patients...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hamadan University of Medical Sciences
2023-06-01
|
| Series: | Avicenna Journal of Medical Biochemistry |
| Subjects: | |
| Online Access: | https://ajmb.umsha.ac.ir/PDF/ajmb-11-46.pdf |
| _version_ | 1797742978649817088 |
|---|---|
| author | Khan Ishrat Jahan Mansoor Ahmed Siddiqui Mohammed Aleemuddin Quamri Hamiduddin Hamiduddin Siddiqui Aafreen |
| author_facet | Khan Ishrat Jahan Mansoor Ahmed Siddiqui Mohammed Aleemuddin Quamri Hamiduddin Hamiduddin Siddiqui Aafreen |
| author_sort | Khan Ishrat Jahan |
| collection | DOAJ |
| description | Background: Chronic Kidney Disease (CKD) is a major public health problem with a global prevalence of approximately 13% with the majority stage 3 and is a global threat to health in general and for developing countries in particular, because therapy is expensive and life-long. In India 90% patients cannot afford the cost of treatment for CKD, over 1 million people worldwide alive on dialysis or with a functioning graft. It is the need of the time to find alternate treatment to control CKD. Hence this study aims to evaluate clinically the efficacy of Kabab Chini (Piper cubeba) in CKD stage 1-3 and also to compare the effectiveness of the marketed drug NEERI KFT® scientifically.
Objectives: To evaluate the efficacy of Kabab Chini (Piper cubeba) in chronic kidney disease (CKD) stage 1-3 patients.
Methods: In this open-labeled randomized controlled clinical trial, 30 participants, randomly allocated to two groups, received 4 g of either sufoof (powder) of Kabab Chini in a divided dose thrice a day (Test group, n=15) or 10 mL of Syrup NEERI-KFT three times a day (Control group, n=15) for 42 days. The objective parameters were serum creatinine, blood urea (BU), estimated glomerular filtration rate (eGFR), and urine routine and microscopy, whereas subjective parameters were anorexia, easy fatigability, and edema. Objective and subjective parameters were assessed at weekly follow-ups, and safety parameters were assessed at baseline and after 42 days.
Results: Intragroup data suggest significant improvements in anorexia, easy fatigability, and eGFR in both groups (P=0.001), whereas the intragroup serum creatinine value was significantly reduced in the test (P=0.028) and control (P=0.256) groups. No significant improvement in edema and albumin was observed in both groups (P>0.05). The test drug was found to be tolerable with no adverse effects.
Conclusion: The results of the present study revealed that Kabab Chini is effective in reducing serum creatinine, eGFR, anorexia, and easy fatigability moderately superior to Syrup NEERI-KFT® with respect to efficacy without any adverse effect and accepted alternate hypothesis. |
| first_indexed | 2024-03-12T14:48:58Z |
| format | Article |
| id | doaj.art-96851bf73b834d29a22baf2e07f1736a |
| institution | Directory Open Access Journal |
| issn | 2345-4113 |
| language | English |
| last_indexed | 2024-03-12T14:48:58Z |
| publishDate | 2023-06-01 |
| publisher | Hamadan University of Medical Sciences |
| record_format | Article |
| series | Avicenna Journal of Medical Biochemistry |
| spelling | doaj.art-96851bf73b834d29a22baf2e07f1736a2023-08-15T21:05:55ZengHamadan University of Medical SciencesAvicenna Journal of Medical Biochemistry2345-41132023-06-01111465410.34172/ajmb.2023.2376Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical TrialKhan Ishrat Jahan0https://orcid.org/0000-0001-9837-3697Mansoor Ahmed Siddiqui1Mohammed Aleemuddin Quamri2Hamiduddin Hamiduddin3Siddiqui Aafreen4Department of Moalajat (Medicine), National Institute of Unani Medicine, Bengaluru, Karnataka, India-560091Department of Moalajat (Medicine), National Institute of Unani Medicine, Bengaluru, Karnataka, India-560091Department of Moalajat (Medicine), National Institute of Unani Medicine, Bengaluru, Karnataka, India-560091Department of Ilmul Saidla (Pharmacy), National Institute of Unani Medicine, Bengaluru, Karnataka, India-560091 Department of Moalajat (Medicine), National Institute of Unani Medicine, Bengaluru, Karnataka, India-560091Background: Chronic Kidney Disease (CKD) is a major public health problem with a global prevalence of approximately 13% with the majority stage 3 and is a global threat to health in general and for developing countries in particular, because therapy is expensive and life-long. In India 90% patients cannot afford the cost of treatment for CKD, over 1 million people worldwide alive on dialysis or with a functioning graft. It is the need of the time to find alternate treatment to control CKD. Hence this study aims to evaluate clinically the efficacy of Kabab Chini (Piper cubeba) in CKD stage 1-3 and also to compare the effectiveness of the marketed drug NEERI KFT® scientifically. Objectives: To evaluate the efficacy of Kabab Chini (Piper cubeba) in chronic kidney disease (CKD) stage 1-3 patients. Methods: In this open-labeled randomized controlled clinical trial, 30 participants, randomly allocated to two groups, received 4 g of either sufoof (powder) of Kabab Chini in a divided dose thrice a day (Test group, n=15) or 10 mL of Syrup NEERI-KFT three times a day (Control group, n=15) for 42 days. The objective parameters were serum creatinine, blood urea (BU), estimated glomerular filtration rate (eGFR), and urine routine and microscopy, whereas subjective parameters were anorexia, easy fatigability, and edema. Objective and subjective parameters were assessed at weekly follow-ups, and safety parameters were assessed at baseline and after 42 days. Results: Intragroup data suggest significant improvements in anorexia, easy fatigability, and eGFR in both groups (P=0.001), whereas the intragroup serum creatinine value was significantly reduced in the test (P=0.028) and control (P=0.256) groups. No significant improvement in edema and albumin was observed in both groups (P>0.05). The test drug was found to be tolerable with no adverse effects. Conclusion: The results of the present study revealed that Kabab Chini is effective in reducing serum creatinine, eGFR, anorexia, and easy fatigability moderately superior to Syrup NEERI-KFT® with respect to efficacy without any adverse effect and accepted alternate hypothesis.https://ajmb.umsha.ac.ir/PDF/ajmb-11-46.pdfckddauf-al-kulyakabab chiniserum creatinineegfrsue mizaj barid kulyaunani |
| spellingShingle | Khan Ishrat Jahan Mansoor Ahmed Siddiqui Mohammed Aleemuddin Quamri Hamiduddin Hamiduddin Siddiqui Aafreen Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial Avicenna Journal of Medical Biochemistry ckd dauf-al-kulya kabab chini serum creatinine egfr sue mizaj barid kulya unani |
| title | Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial |
| title_full | Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial |
| title_fullStr | Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial |
| title_full_unstemmed | Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial |
| title_short | Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial |
| title_sort | efficacy of kabab chini piper cubeba linn in chronic kidney disease a randomized controlled clinical trial |
| topic | ckd dauf-al-kulya kabab chini serum creatinine egfr sue mizaj barid kulya unani |
| url | https://ajmb.umsha.ac.ir/PDF/ajmb-11-46.pdf |
| work_keys_str_mv | AT khanishratjahan efficacyofkababchinipipercubebalinninchronickidneydiseasearandomizedcontrolledclinicaltrial AT mansoorahmedsiddiqui efficacyofkababchinipipercubebalinninchronickidneydiseasearandomizedcontrolledclinicaltrial AT mohammedaleemuddinquamri efficacyofkababchinipipercubebalinninchronickidneydiseasearandomizedcontrolledclinicaltrial AT hamiduddinhamiduddin efficacyofkababchinipipercubebalinninchronickidneydiseasearandomizedcontrolledclinicaltrial AT siddiquiaafreen efficacyofkababchinipipercubebalinninchronickidneydiseasearandomizedcontrolledclinicaltrial |